
|Articles|February 1, 2003
Increased tear production: Restasis approval a milestone for dry eye
The FDA approval of cyclosporine ophthalmic emulsion 0.05% (Restasis, Allergan) Dec. 26 marked a landmark for ophthalmology. The eye drop therapy for moderate to severe keratoconjunctivitis sicca is unique in that it treats the inflammatory process that causes the condition, and not just its symptoms.
Advertisement
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
STAAR, Broadwood reach cooperation agreement, restructure board after terminated Alcon deal
2
Ophthalmology pipeline watch: Key trial results and PDUFA dates for Q1 2026
3
PRIMA retinal implant restores vision in patients with advanced GA
4
Ocugen releases positive preliminary 12-month data from phase 2 ArMaDa trial
5














































